Gustavo Mahler
Venture Partner @ Dynamk Capital
Seattle, United States
Gustavo Mahler is a Series A investor at Dynamk Capital in Seattle focused on Biotechnology and Medical. Dr. Gustavo Mahler is a Venture Partner of Dynamk Capital LLC, having served as an Advisor to Dynamk since 2017. In 2015, Dr. Mahler became CEO of CMC Biologics, and he was a key player in the sale of CMC Biologics to the Asahi Glass Corporation in 2017. Dr. Mahler holds a Ph.D. in Biochemistry from the University of Buenos Aires, an MBA from theUniversity of Madrid and a Leadership and Management Certification from MIT Sloan School of Management.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 78%
Last updated:
For AI agents: llms.txt
Industries Gustavo Mahler invests in
Stages Gustavo Mahler invests in
Countries Gustavo Mahler invests in
Investment Focus
Industry
- Biotechnology 4 (44%)
- Medical 3 (33%)
- Life Science 2 (22%)
- Biopharma 1 (11%)
- Health Care 1 (11%)
Stage
- Series A 4 (44%)
- Seed 2 (22%)
- Funding Round 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CellFE
|
CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells. | $22M / Series A / Sep 27, 2023 | |
Vernal Biosciences
|
Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis. | $20M / Series A / Jun 27, 2023 | |
|
Vernal Biosciences
|
Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis. | $21M / Jun 02, 2022 | |
|
Vernal Biosciences
|
Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis. | $21M / Series A / Jun 02, 2022 | |
Curi Bio
|
Curi Bio is a biotechnology company that focuses on advancing drug discovery and development through innovative approaches involving human stem cells, systems biology, and data analytics. The company's primary goal is to accelerate the process of identifying and developing new medicines.Curi Bio's platform revolves around the use ofhuman stem cells, which have the potential to be differentiated into various cell types, replicating the behavior of different tissues and organs. This allows researchers to create more accurate and relevant models for studying disease mechanisms and testing potential drug candidates.NanoSurface Biomedical Is Now Curi Bio. | $10M / Series A / Dec 29, 2021 | |
Alpenglow Biosciences
|
Alpenglow Biosciences is an end-to-end 3D pathology platform. Lightspeed Microscopy reimagines pathology by providing a full-stack solution to nondestructively image large tissues in 3D at sub-cellular resolution. Its novel chemistry patented high-throughput light-sheet microscope, and cloud-based AI analysis software adds a new dimension topathology. | $4M / Series A / Jun 15, 2021 | |
|
Curi Bio
|
Curi Bio is a biotechnology company that focuses on advancing drug discovery and development through innovative approaches involving human stem cells, systems biology, and data analytics. The company's primary goal is to accelerate the process of identifying and developing new medicines.Curi Bio's platform revolves around the use ofhuman stem cells, which have the potential to be differentiated into various cell types, replicating the behavior of different tissues and organs. This allows researchers to create more accurate and relevant models for studying disease mechanisms and testing potential drug candidates.NanoSurface Biomedical Is Now Curi Bio. | $6M / Series A / Mar 18, 2021 | |
Lucid Scientific
|
Lucid Scientific is a biotechnology tools company working to accelerate drug discovery and basic biological research by providing systems for real-time cellular analysis. It has invented an innovative new system for monitoring cell culture experiments. The company’s flagship technology, called RESIPHER, provides continuous and non-invasivemeasurement of oxygen consumption in a cell culture plate, then streams this information to a convenient web app. | $3M / Seed / Oct 01, 2020 | |
|
CellFE
|
CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells. | $4.8M / Seed / Jan 16, 2020 |
Co-Investors
Charles River Laboratories International
3 deals together
Alloy Therapeutics
2 deals together
Ampersand Capital Partners
2 deals together
Cota Capital
2 deals together
Elm Street Ventures
2 deals together
Embark Ventures
2 deals together
About Dynamk Capital
Dynamk Capital invests in innovative tools and technologies that are critical for the discovery, development and production of life-saving therapies.We partner with life science visionaries whose market-defining ideas are shaping the future of how therapeutics are being developed, increasing access for patients, and reducing costs.
Dynamk Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Daniella Kranjac
Founding Partner
|
|||
Reinhard Vogt
Managing Director
|
|||
|
Gustavo Mahler
Venture Partner
|
|||
Sebastien Latapie
Principal
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Gustavo Mahler invest in?
Gustavo Mahler invests primarily in Biotechnology, Medical and Life Science startups, most often at Series A and Seed stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Gustavo Mahler last invest?
The most recent investment recorded for Gustavo Mahler closed in Sep 2023. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
